Articles published by Epicrispr Biotechnologies

Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD

January 08, 2026

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference

December 08, 2025

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy

August 05, 2025

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize

May 12, 2025

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting

May 05, 2025

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study

April 23, 2025

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD

April 03, 2025

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD

March 26, 2025

From Epicrispr Biotechnologies

Via Business Wire

Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT

October 22, 2024

From Epicrispr Biotechnologies

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Epicrispr Biotechnologies

Starting at $3.75/week.

Subscribe Today